1 results match your criteria: "6 Scripps Clinic[Affiliation]"
Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model.
J Ocul Pharmacol Ther
March 2017
6 Scripps Clinic, La Jolla, California.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of a sustained-release dexamethasone insert (Dextenza™) for allergic conjunctivitis.
- The randomized, double-masked trial included subjects with positive allergen reactions, assessing outcomes like itching and redness over 42 days following treatment.
- Results showed Dextenza performed better than the vehicle insert in reducing symptoms, although clinical significance was not fully achieved, with both groups reporting a similar rate of adverse events.